NCT02551432View on ClinicalTrials.gov

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2018

Conditions
Small Cell Lung Cancer
Interventions
DRUG

pembrolizumab, paclitaxel

pembrolizumab, paclitaxel

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02551432 - Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter